IP Library Granted Patent US 7,641,337
Granted Patent B2
US 7,641,337 · App. 11/615,491 · Granted Jan 5, 2010

Ophthalmic lens including photochromic material

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,641,337
App. No.
11/615,491
Filed
Dec 22, 2006
Granted
Jan 5, 2010
Kind
B2
Art Unit
2873
USPC
351/165
Abstract

An ophthalmic lens, comprising an optic including at least one photochromic region having a first chromaticity and a second region of lesser photochromaticity. A method of treating a subject having presbyopia or aniridia comprising applying to the subject's eye an ophthalmic lens comprising an optic including at least one photochromic region having a first chromaticity and a second region of lesser photochromaticity.

Claims (35)

1. An ophthalmic lens having an optical axis, comprising:

an optic including

(i) at least one photochromic region, and

(ii) a second region of lesser photochromaticity than the at least one photochromic region, the second region having the optical axis extending therethrough, the second region extending from the optical axis to a radius r, where 0.5 ≦r <1.5 mm,

the at least one photochromic region substantially surrounding the second region, wherein the at least one photochromic region is bounded by inner and outer boundaries, the at least one photochromic region having a non-zero concentration of chromaphores at locations between the boundaries, the non-zero concentration of chromaphores varying as a function of radial position such that the at least one photochromic region transmits more light closer to the optical axis than further from the optical axis, wherein the lens is adapted to be applied to an eye and adapted to permit light to transmit through the lens to the retina when applied to the eye.

2. The ophthalmic lens in claim 1 , wherein the at least one photochromic region completely surrounds the second region.

3. The ophthalmic lens in claim 2 , wherein the second region is circular.

4. The ophthalmic lens in claim 1 , wherein the lens is multifocal.

5. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a broadband photochromic material for visible light.

6. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a neutral density photochromic material for visible light.

7. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a photochromic material that is a low pass filter of visible light.

8. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a photochromic material that is a high pass filter of visible light.

9. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a photochromic material that is a band pass filter of visible light.

10. The ophthalmic lens in claim 1 , wherein the photochromic region comprises a photochromic material that is a notch filter of visible light.

11. The ophthalmic lens in claim 1 , wherein the second region has a concentration of chromophores that varies linearly as a function of radial position.

12. The ophthalmic lens in claim 1 , wherein the optic includes at least two photochromic regions having a first chromaticity.

13. The ophthalmic lens in claim 1 , wherein the second region has substantially no chromophores.

14. The ophthalmic lens in claim 1 , wherein the lens is an intraocular lens.

15. The ophthalmic lens in claim 1 , wherein the lens is a contact lens.

16. The ophthalmic lens in claim 1 , wherein the lens is a corneal inlay or a corneal onlay.

17. The ophthalmic lens in claim 1 , wherein the lens has optical power.

18. The ophthalmic lens of claim 1 , wherein, the concentration of chromaphores varies continuously as a function of radial position.

19. A method of treating a subject's eye, the eye having an iris and a retina, the method comprising:

applying to the subject's eye an ophthalmic lens having an optical axis, the lens comprising an optic including

(i) at least one photochromic region and

(ii) a second region of lesser photochromaticity than the at least one photochromic region, the second region having the optical axis extending therethrough, the second region extending from the optical axis to a radius r, where 0.5 ≦r <1.5 mm,

the at least one photochromic region substantially surrounding the second region, wherein the lens is adapted to permit light to transmit through the lens to the retina after application to the eye.

20. The method in claim 19 , wherein the at least one photochromic region completely surrounds the second region.

21. The method in claim 19 , wherein the second region is circular.

22. The method in claim 19 , wherein the second region has substantially no chromophores.

23. The method in claim 19 , wherein the step of applying an ophthalmic lens comprises implanting an intraocular lens in the eye.

24. The method in claim 19 , wherein the step of applying an ophthalmic lens comprises depositing a contact lens on the eye.

25. The method in claim 19 , wherein the step of applying an ophthalmic lens comprises applying a corneal inlay or a corneal onlay to the eye.

26. The method of claim 19 , wherein the at least one photochromic region is bounded by inner and outer boundaries, the at least one photochromic region having a non-zero concentration of chromaphores at locations between the boundaries, the non-zero concentration of chromaphores varying as a function of radial position such that the at least one photochromic region transmits more light closer to the optical axis than further from the optical axis.

27. The method of claims 26 , wherein the concentration of chromaphores varies continuously as a function of radial position.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →